Artelo Biosciences
ARTL
2 hedge funds and large institutions have $43K invested in Artelo Biosciences in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0.64% less ownership
Funds ownership: 1.21% → 0.57% (-0.64%)
77% less capital invested
Capital invested by funds: $189K → $43K (-$146K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$41.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$189K |
ARTL Hedge Fund Activity: Q3 2019 in Review
2 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2019, worth a combined $43K — down 77% from $189K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ARTL positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $41.2K. The largest seller was CVI Holdings, exiting entirely with an estimated $189K sold.
- 2 institutional investors held Artelo Biosciences (ARTL) as of Q3 2019, up from 1 in Q2 2019.
- Funds reported $43K of Artelo Biosciences stock for Q3 2019, down 77% quarter-over-quarter.
- 2 funds opened new Artelo Biosciences positions in Q3 2019 and 1 closed out, a net change of +1 holder.
- The largest Artelo Biosciences buyer in Q3 2019 was Goldman Sachs, an estimated $41.2K added.
- The largest Artelo Biosciences seller in Q3 2019 was CVI Holdings, an estimated $189K sold.
Based on aggregated 13F filings for Q3 2019.